iCAD’s Xoft Intraoperative Radiation Therapy System Featured at American Society of Breast Surgeons Conference

  iCAD’s Xoft Intraoperative Radiation Therapy System Featured at American
  Society of Breast Surgeons Conference

American Society of Breast Surgeons' 14th Annual Meeting Booth #303

Business Wire

NASHUA, N.H. & CHICAGO -- May 3, 2013

Booth #303--iCAD, Inc. (Nasdaq: ICAD), a leading provider of advanced imaging
and radiation therapy technologies for the detection and treatment of cancer,
today announced that the Company’s Xoft^® Axxent^® Electronic Brachytherapy
System^® for Intraoperative Radiation Therapy (IORT) will be a featured
subject of several scientific and training sessions at the American Society of
Breast Surgeons’ 14^th Annual Meeting taking place this week at the Sheraton
Chicago Hotel & Towers.

“We are pleased to have our Xoft System for the treatment of early-stage
breast cancer so prominently featured before an audience of more than 1,000 of
the world’s top breast surgeons at this premiere medical conference,” said Ken
Ferry, President and CEO of iCAD. “The data presented further confirm the
benefits of this therapy, and we look forward to new and continued
opportunities to advance the treatment of breast cancer and improve the lives
of patients.”

IORT data and innovations will be discussed in the following poster and
educational session:

  *“Intra-Operative Radiation Therapy for Treatment of Early Stage Breast
    Cancer: Short Term Results from a Single Institution Clinical Trial Using
    Electronic Brachytherapy with a Disposable Balloon Applicator”
    The poster (#56) will be available for viewing as of 9:30 a.m. CT on
    Friday, May 3
    Chicago Room 8-10, Level IV, Row J.
    Barbara S. Schwartzberg, MD, Rose Medical Center, Denver, Colo., will
    review the results of a 51-patient trial of the Xoft^® Axxent^® Electronic
    Brachytherapy System^®, finding no recurrences of breast cancer at an
    average of 14 months post-treatment from 6:00 p.m.-7:30 p.m. CTon Friday
    evening at the poster location.

  *“Innovations and Advances in Breast Cancer Diagnosis and Treatment”
    Friday, May 3, 4:00 p.m.-5:30 p.m. CT
    Sheraton Chicago 4–7, Level IV
    The IORT portion of the General Session discussion will be led by Darius
    S. Francescatti, MD, JD, FACS, Assistant Professor, Rush Presbyterian St.
    Luke’s Medical Center, Chicago, Ill.

“IORT is a significant advancement in the treatment of breast cancer, offering
women a less burdensome option to traditional radiation therapy and mitigating
the arduous road to recovery many of these patients face,” said Dr.
Schwartzberg. “The data presented today show positive outcomes with no
recurrence of cancer, further validating the efficacy of IORT for women with
early-stage breast cancer.”

About Xoft^® Axxent^® Electronic Brachytherapy System^®

The Xoft System is an isotope-free radiation treatment cleared by the U.S.
Food and Drug Administration and CE marked for use anywhere in the body,
including for the treatment of early-stage breast cancer, endometrial cancer,
cervical cancer and skin cancer. It utilizes a proprietary miniaturized x-ray
as the radiation source that delivers precise treatment directly to cancerous
areas while sparing healthy tissue and organs. A post-market study is underway
to assess the safety and efficacy of Intraoperative Radiation Therapy with the
Xoft System. Xoft, Inc. is a wholly owned subsidiary of iCAD, Inc. For more
information about Xoft visit www.xoftinc.com.

About iCAD, Inc.

iCAD is a leading provider of advanced image analysis, workflow solutions and
radiation therapies for the early identification and treatment of common
cancers. iCAD offers a comprehensive range of high-performance, upgradeable
CAD solutions for mammography and advanced image analysis and workflow
solutions for Magnetic Resonance Imaging, for breast and prostate cancers and
Computed Tomography for colorectal cancer. iCAD’s Xoft System, offers
radiation treatment for early-stage breast cancer that can be administered in
the form of Intraoperative Radiation Therapy or accelerated partial breast
irradiation. The Xoft System is also cleared for the treatment of non-melanoma
skin cancer, endometrial and cervical cancers. For more information, call
877-iCADnow, or visit www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of

Certain statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve a number of known and unknown
risks, uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially different from any
future results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited to, the
Company’s ability to defend itself in litigation matters, the risks relating
to the Company’s acquisition of Xoft including, the expected benefits of the
acquisition may not be achieved in a timely manner, or at all; the Xoft
business operations may not be successfully integrated with iCAD’s and iCAD
may be unable to achieve the expected synergies, business and strategic
objectives following the transaction, the risks of uncertainty of patent
protection; the impact of supply and manufacturing constraints or
difficulties; product market acceptance; possible technological obsolescence;
increased competition; customer concentration; and other risks detailed in the
Company’s filings with the Securities and Exchange Commission. The words
“believe”, “demonstrate”, “intend”, “expect”, “estimate”, “will”, “continue”,
“anticipate”, “likely”, and similar expressions identify forward-looking
statements. Readers are cautioned not to place undue reliance on those
forward-looking statements, which speak only as of the date the statement was
made. The Company is under no obligation to provide any updates to any
information contained in this release. For additional disclosure regarding
these and other risks faced by iCAD, please see the disclosure contained in
our public filings with the Securities and Exchange Commission, available on
the Investors section of our website at http://www.icadmed.com and on the
SEC’s website at http://www.sec.gov.


For iCAD
Kevin Burns, 937-431-7967
For iCAD investor relations
Anne Marie Fields, 212-838-3777 x6604
For iCAD media inquiries
Schwartz MSL
Helen Shik, 781-684-0770
Press spacebar to pause and continue. Press esc to stop.